Home Newsfeeds Kalera Q2 EPS $(3.92)

Kalera Q2 EPS $(3.92)

Net loss of $78.7 million, or a loss of $3.92 per diluted share, which included a one-time non-cash expense for goodwill impairment of $64.3 million, the change in fair value for the contingent

byBill Haddad

August 19, 2022

1 minute read

Net loss of $78.7 million, or a loss of $3.92 per diluted share, which included a one-time non-cash expense for goodwill impairment of $64.3 million, the change in fair value for the contingent value rights earnout of $17.3 million and a one-time expense of $7.5 million related to the closing of the Agrico business combination and Nasdaq listing.

HC Wainwright & Co. Initiates Coverage On Vizsla Silver with Buy Rating, Announces Price Target of $1.6

By Benzinga Newsdesk

July 28, 6:14 AM

HC Wainwright & Co. analyst Heiko Ihle initiates coverage on Vizsla Silver (AMEX:VZLA) with a Buy rating and announces Price Target of $1.6.

VZLA

Morgan Stanley Maintains Equal-Weight on Artivion, Lowers Price Target to $21

By Benzinga Newsdesk

July 15, 9:53 AM

Morgan Stanley analyst Cecilia Furlong maintains Artivion (NYSE:AORT) with a Equal-Weight and lowers the price target from $23 to $21.

AORT

Madrigal Announced Topline Results from the Pivotal Phase 3 MAESTRO-NASH Clinical Trial of Resmetirom for the Treatment of NASH and Liver Fibrosis; Potentially Clinically Meaningful LDL-lowering, a Key Secondary Endpoint

By Charles Gross

December 19, 8:07 AM

Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today provides an overview of upcoming resmetirom Phase 3 data presentations and reports third quarter 2022 financial results.

MDGL